Subtopic Deep Dive
Gastrointestinal Stromal Tumor Treatment
Research Guide
What is Gastrointestinal Stromal Tumor Treatment?
Gastrointestinal Stromal Tumor Treatment encompasses targeted kinase inhibitor therapies like imatinib and sunitinib alongside surgical resection for KIT/PDGFRA-mutant GISTs.
GIST treatment relies on mutation-specific responses to imatinib, with primary KIT exon 11 mutations showing high response rates (Heinrich et al., 2003; 2278 citations). Sunitinib provides second-line efficacy in imatinib-resistant cases by targeting secondary kinase genotypes (Heinrich et al., 2008; 798 citations). Clinical guidelines integrate these with surgery and follow-up (Casali et al., 2018; 746 citations). Over 10 key papers span 2003-2018.
Why It Matters
GIST treatment established precision oncology in sarcomas through KIT/PDGFRA genotyping guiding imatinib use, achieving response rates up to 83% in exon 11 mutants (Heinrich et al., 2003). Sunitinib extended progression-free survival in resistant GIST from 6 to 24 weeks via multi-kinase inhibition (Heinrich et al., 2008). NCCN guidelines apply these to soft tissue sarcomas, influencing surgical timing and adjuvant therapy (von Mehren et al., 2018). ESMO-EURACAN protocols standardize diagnosis-to-follow-up, reducing recurrence via risk stratification (Casali et al., 2018).
Key Research Challenges
Imatinib Resistance Mechanisms
Secondary KIT mutations emerge in 50-70% of patients, reducing imatinib efficacy (Heinrich et al., 2003). Genotyping correlates primary/secondary mutations with response, but novel variants challenge prediction (Heinrich et al., 2008).
Second-Line Therapy Optimization
Sunitinib targets resistant genotypes but shows variable activity by mutation type (Heinrich et al., 2008). Clinical trials identify optimal sequencing post-imatinib failure (Maki et al., 2009).
Mutation-Specific Prognosis
KIT exon 11 mutations predict better imatinib response than exon 9, but PDGFRA variants resist (Heinrich et al., 2003). Integrating morphology and molecular pathology refines risk assessment (Miettinen and Lasota, 2006).
Essential Papers
Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
Michael C. Heinrich, Christopher L. Corless, George D. Demetri et al. · 2003 · Journal of Clinical Oncology · 2.3K citations
Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential the...
Somatic Activation of KIT in Distinct Subtypes of Melanoma
John A. Curtin, Klaus J. Busam, Daniel Pinkel et al. · 2006 · Journal of Clinical Oncology · 1.6K citations
Purpose Melanomas on mucosal membranes, acral skin (soles, palms, and nail bed), and skin with chronic sun-induced damage have infrequent mutations in BRAF and NRAS, genes within the mitogen-activa...
Gastrointestinal Stromal Tumors: Review on Morphology, Molecular Pathology, Prognosis, and Differential Diagnosis
Markku Miettinen, Jerzy Lasota · 2006 · Archives of Pathology & Laboratory Medicine · 1.4K citations
Abstract Context.—Gastrointestinal stromal tumors (GISTs) are specific, generally Kit (CD117)-positive, mesenchymal tumors of the gastrointestinal tract encompassing a majority of tumors previously...
Biology of Gastrointestinal Stromal Tumors
Christopher L. Corless, Jonathan A. Fletcher, Michael C. Heinrich · 2004 · Journal of Clinical Oncology · 1.2K citations
Once a poorly defined pathologic oddity, in recent years, gastrointestinal stromal tumor (GIST) has emerged as a distinct oncogenetic entity that is now center stage in clinical trials of kinase-ta...
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich, Robert G. Maki, Christopher L. Corless et al. · 2008 · Journal of Clinical Oncology · 798 citations
Purpose Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor α (PDGFRA) kinases, which are imatinib targets. Sunitinib, which targets KIT, PDGFR...
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Paolo G. Casali, N. Abecassis, Sebastian Bauer et al. · 2018 · Annals of Oncology · 746 citations
Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin et al. · 2018 · Journal of the National Comprehensive Cancer Network · 720 citations
Soft tissue sarcomas (STS) are rare solid tumors of mesenchymal cell origin that display a heterogenous mix of clinical and pathologic characteristics. STS can develop from fat, muscle, nerves, blo...
Reading Guide
Foundational Papers
Start with Heinrich et al. (2003) for imatinib-mutation correlations (2278 citations), then Corless et al. (2004) for GIST biology, and Heinrich et al. (2008) for sunitinib genotyping.
Recent Advances
Casali et al. (2018) ESMO guidelines for practice standards; von Mehren et al. (2018) NCCN for sarcoma integration.
Core Methods
KIT/PDGFRA sequencing for therapy selection (Heinrich et al., 2003); multi-kinase inhibition (Heinrich et al., 2008); risk stratification via morphology/genotype (Miettinen and Lasota, 2006).
How PapersFlow Helps You Research Gastrointestinal Stromal Tumor Treatment
Discover & Search
Research Agent uses searchPapers('GIST imatinib resistance') to retrieve Heinrich et al. (2003), then citationGraph maps 2278 citing papers on KIT mutations, and findSimilarPapers expands to sunitinib studies like Heinrich et al. (2008). exaSearch uncovers guideline updates from Casali et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent on Heinrich et al. (2003) to extract mutation-response data, verifyResponse with CoVe checks claims against Corless et al. (2004), and runPythonAnalysis plots survival curves from extracted tables using pandas/matplotlib. GRADE grading scores evidence as high for imatinib efficacy (Level 1b from RCTs).
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-sunitinib via contradiction flagging across Heinrich papers, then Writing Agent uses latexEditText for treatment algorithm drafts, latexSyncCitations links to 10 GIST papers, and latexCompile generates review sections. exportMermaid visualizes KIT mutation pathways.
Use Cases
"Extract survival data from GIST imatinib trials and plot PFS curves"
Research Agent → searchPapers → Analysis Agent → readPaperContent(Heinrich 2003/2008) → runPythonAnalysis(pandas plot) → matplotlib PFS graph output.
"Draft LaTeX review on GIST treatment guidelines"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(Casali 2018, von Mehren 2018) → latexCompile → PDF output.
"Find code for KIT mutation analysis in GIST papers"
Research Agent → searchPapers(GIST kinase) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → R scripts for genotype clustering.
Automated Workflows
Deep Research workflow scans 50+ GIST papers via searchPapers → citationGraph → structured report on imatinib-to-sunitinib progression (Heinrich et al.). DeepScan applies 7-step CoVe analysis to verify mutation correlations from Heinrich (2003). Theorizer generates hypotheses on third-line therapies from resistance patterns in Maki et al. (2009).
Frequently Asked Questions
What defines GIST treatment?
Targeted therapy with imatinib for KIT/PDGFRA mutants plus surgery; response ties to exon 11 mutations (Heinrich et al., 2003).
What methods drive GIST therapy?
Kinase genotyping predicts imatinib response; sunitinib follows for resistant cases via multi-kinase targeting (Heinrich et al., 2008).
What are key papers?
Heinrich et al. (2003; 2278 citations) on mutations/imatinib; Heinrich et al. (2008; 798 citations) on sunitinib; Casali et al. (2018) guidelines.
What open problems exist?
Overcoming secondary mutations beyond sunitinib; optimizing combinations for PDGFRA variants (Heinrich et al., 2008; Maki et al., 2009).
Research Sarcoma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching Gastrointestinal Stromal Tumor Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Sarcoma Diagnosis and Treatment Research Guide